RE:Ardelyx, portalix biotherapeutics taking off today The Ardelyx drug is now doing about a million per year in sales for us. The relative growth rate is nice but in absolute numbers it's still quite low. According to Ardelyx's latest 10-K, we've so far paid 2.3 million for the license in up-front payments. Based on GUD's reports, our total revenue for the drug is somewhere around 1.6 million so far. There's still potential for 20+ million in payments related to milestones and such, but I don't think we're going to end-up paying anything close to that. The drug would have to grow aggressively in relative terms for us to pay eight figures in milestone payments.
Was there an equity investment in Ardelyx as well? Haven't found a mention of that.
And regarding Portalix, I assume that went away with Medison? Haven't found any mention of the company in the more recent reports.